Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

USAK, TSX.V:MJS, USNA, PWRM, USU - CRWEFinance.com Stock Report! Nov 29th 2010

crwefinancelogo2

signup3m

USA Truck, Inc. (Nasdaq:USAK) announced base revenue of $100.8 million for the quarter ended September 30, 2010, an increase of 22.4% from $82.3 million for the same quarter of 2009.

USA Truck, Inc. operates as a truckload carrier that provides general commodities transportation services in the continental United States, Mexico, and Canada. The company transports full dry van trailer loads of freight from origin to destination.

**************************************************************************

http://pennyomega.com/img/mjs.jpg

Majestic Gold Corp. (TSX.V:MJS) (”Majestic”) engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

http://pennyomega.com/img/mjs_highlight2.jpg

Majestic Gold Corp. (TSX.V:MJS) (”Majestic”) recently announced the results of an updated resource estimate on its Song Jiagou Mine.

As part of the ongoing assessment on the Song Jiagou Mine, Wardrop Engineering Inc. (”Wardrop”) has revised their previous resource estimate (NR 23 April, 2010) as a result of the revision to the contract mining costs (NR 30 September 2010) which allowed cut-off grades to be reduced from 0.40 g/t to 0.30 g/t and warranted a revision of the block model.

Subsequent to the initial resource estimate, Wardrop determined that rotating the block model perpendicular to drilling direction was the most favorable orientation to evaluate the deposit and to calculate the revised resource. The new cut-off grade and the re-orientation of the model significantly increased the overall size of the resource and the contained ounces of gold in both the inferred and indicated categories.

The most significant changes from the previous estimate are:

* Increase in Indicated tonnes by 35.34% to 33,739,586 tonnes
* Increase in Indicated contained gold by 24.09% to 1,244,211 ounces
* Increase in Inferred tonnes by 37.96% to 38,812,054 tonnes
* Increase in Inferred contained gold by 7.48% to 1,830,576 ounces

The increase in the size of the resource from 53 to 72.5 million tonnes will very significantly reduce the strip ratios to be used as Majestic continues its engineering studies on the Song Jiagou mine. Wardrop will move forward now to re-evaluate a production pit design.

Majestic continues to work with Wardrop and its sister company, Tetra Tech (Beijing) Consultancy Company Limited, (both subsidiaries of Terta Tech Inc.) to complete a Preliminary Economic Assessment, concurrent with the required Chinese Geological and Engineering studies required to apply for increased production levels at Song Jiagou. The results of these studies will ultimately culminate in a Pre-feasibility report.

More about (TSX.V:MJS) at: www.majesticgold.net

**************************************************************************

USANA Health Sciences, Inc. (NASDAQ:USNA) announced record financial results for its fiscal third quarter ended October 2, 2010. Net sales in the third quarter of 2010 increased 21.9% to $135.0 million, compared with $110.7 million in the third quarter of the prior year.

USANA Health Sciences, Inc. engages in the development, manufacture, and sale of nutritional and personal care products in North America and the Asia Pacific.

**************************************************************************

USEC Inc. (NYSE:USU) has begun talks with the U.S. Department of Energy step toward a conditional commitment to finance construction of the American Centrifuge Plant. The project will support nearly 8,000 jobs during its construction.

USEC Inc., a global energy company, is a leading supplier of enriched uranium fuel for commercial nuclear power plants.

**************************************************************************

Power3 Medical Products Inc (OTC.BB:PWRM) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

PWRM has filed several patent applications for its NuroPro technology that are currently pending. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. PWRM intends to publish these latest findings as well. PWRM a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

PWRM has also signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

PWRM strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

More about PWRM at: www.Power3Medical.com

********************************************************************

http://crwefinance.com/img/crwefinance_new_buscard2.jpg

Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty-five thousand dollars in cash from Majestic Gold Corp. (TSX Venture Exchange (TSX.V:MJS) and the Frankfurt Stock Exchange (FSE:MJT)) for 30 (thirty) days of advertising, as well as for assistance in becoming a fully reporting publicly trading Bulletin Board company. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).